新冠病毒COVID-19-话题@MedSci

#新冠病毒COVID-19#

26篇内容 | 1146人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1851041, encodeId=fe0418510410f, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段, objectType=article, longId=197185, objectId=861519e185ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861519e185ee, replyNumber=0, likeNumber=46, createdTime=2021-06-08, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861519e185ee, moduleTitle=Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861519e185ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851038, encodeId=7717185103806, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=地塞米松真的是新冠病毒COVID-19的突破吗？医生说先别着急, objectType=article, longId=196070, objectId=1f1a1960e0d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f1a1960e0d8, replyNumber=0, likeNumber=0, createdTime=2020-10-06, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f1a1960e0d8, moduleTitle=地塞米松真的是新冠病毒COVID-19的突破吗？医生说先别着急, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f1a1960e0d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851046, encodeId=9e16185104619, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=6000名患者回顾性研究：明确更有效的抗新冠病毒COVID-19细胞因子风暴疗法, objectType=article, longId=202355, objectId=136420235500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=136420235500, replyNumber=0, likeNumber=30, createdTime=2020-11-23, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=136420235500, moduleTitle=6000名患者回顾性研究：明确更有效的抗新冠病毒COVID-19细胞因子风暴疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=136420235500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851045, encodeId=d87a18510455b, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性, objectType=article, longId=201999, objectId=9dcd20199981, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dcd20199981, replyNumber=0, likeNumber=29, createdTime=2021-01-11, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dcd20199981, moduleTitle=瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dcd20199981)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851039, encodeId=9fbf185103993, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败, objectType=article, longId=196982, objectId=867e19698235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=867e19698235, replyNumber=0, likeNumber=46, createdTime=2020-12-07, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=867e19698235, moduleTitle=IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=867e19698235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851040, encodeId=190c185104082, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=欧盟批准Gilead的remdesivir，治疗新冠病毒COVID-19感染, objectType=article, longId=197033, objectId=67e319e03325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e319e03325, replyNumber=0, likeNumber=39, createdTime=2021-03-01, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e319e03325, moduleTitle=欧盟批准Gilead的remdesivir，治疗新冠病毒COVID-19感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e319e03325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851021, encodeId=40bd1851021e1, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=流行病防范创新联盟发出呼吁，还有20亿美元的资金缺口可能会阻碍新冠病毒COVID-19疫苗的开发, objectType=article, longId=189580, objectId=a97118958050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a97118958050, replyNumber=0, likeNumber=33, createdTime=2020-09-15, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a97118958050, moduleTitle=流行病防范创新联盟发出呼吁，还有20亿美元的资金缺口可能会阻碍新冠病毒COVID-19疫苗的开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a97118958050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851044, encodeId=cd841851044db, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=新型干细胞疗法：治疗新冠病毒COVID-19相关性呼吸窘迫, objectType=article, longId=201998, objectId=26ca2019984c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26ca2019984c, replyNumber=0, likeNumber=35, createdTime=2021-03-10, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26ca2019984c, moduleTitle=新型干细胞疗法：治疗新冠病毒COVID-19相关性呼吸窘迫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26ca2019984c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851043, encodeId=500d185104365, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=FDA发布新冠病毒COVID-19疫苗批准的新指南, objectType=article, longId=201993, objectId=2e16201993c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e16201993c0, replyNumber=0, likeNumber=37, createdTime=2021-09-22, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e16201993c0, moduleTitle=FDA发布新冠病毒COVID-19疫苗批准的新指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e16201993c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851032, encodeId=9aba18510323f, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=西奈山索伦托合作开发针对新冠病毒COVID-19的三抗体联合疗法COVI-SHIELD, objectType=article, longId=193859, objectId=b66d1938590a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b66d1938590a, replyNumber=0, likeNumber=32, createdTime=2020-05-09, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b66d1938590a, moduleTitle=西奈山索伦托合作开发针对新冠病毒COVID-19的三抗体联合疗法COVI-SHIELD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b66d1938590a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851033, encodeId=cd86185103340, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=Moderna将于7月开始，开展其新冠病毒COVID-19疫苗的关键3期试验, objectType=article, longId=195328, objectId=f30519532868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f30519532868, replyNumber=0, likeNumber=35, createdTime=2020-12-02, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f30519532868, moduleTitle=Moderna将于7月开始，开展其新冠病毒COVID-19疫苗的关键3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f30519532868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851034, encodeId=a6a618510342a, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=礼来启动新冠病毒COVID-19抗体药物的全球临床试验, objectType=article, longId=195466, objectId=861d19546646, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861d19546646, replyNumber=0, likeNumber=32, createdTime=2021-03-03, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861d19546646, moduleTitle=礼来启动新冠病毒COVID-19抗体药物的全球临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861d19546646)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851027, encodeId=87bc185102e52, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, objectType=article, longId=191476, objectId=71041914e630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71041914e630, replyNumber=0, likeNumber=37, createdTime=2020-08-03, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71041914e630, moduleTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71041914e630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851042, encodeId=cb78185104281, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=Moderna的新冠病毒COVID-19疫苗：计划定价为每疗程50-60美元, objectType=article, longId=198586, objectId=924719858664, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=924719858664, replyNumber=0, likeNumber=41, createdTime=2020-08-12, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=924719858664, moduleTitle=Moderna的新冠病毒COVID-19疫苗：计划定价为每疗程50-60美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=924719858664)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851029, encodeId=8acf185102972, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验, objectType=article, longId=192249, objectId=f473192249cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f473192249cd, replyNumber=0, likeNumber=34, createdTime=2021-01-09, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f473192249cd, moduleTitle=JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f473192249cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851028, encodeId=f4561851028cc, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=Tiziana实现"肺部靶向递送"抗IL-6R单抗，以高效治疗新冠病毒COVID-19感染患者, objectType=article, longId=191955, objectId=4b1f1919554f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b1f1919554f, replyNumber=0, likeNumber=39, createdTime=2021-01-28, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b1f1919554f, moduleTitle=Tiziana实现"肺部靶向递送"抗IL-6R单抗，以高效治疗新冠病毒COVID-19感染患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b1f1919554f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851037, encodeId=6768185103e20, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=重磅！英国批准全球最佳治疗新冠病毒COVID-19的药物——地塞米松, objectType=article, longId=196069, objectId=c76b196069d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c76b196069d1, replyNumber=0, likeNumber=27, createdTime=2020-09-25, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c76b196069d1, moduleTitle=重磅！英国批准全球最佳治疗新冠病毒COVID-19的药物——地塞米松, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c76b196069d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851035, encodeId=72e9185103515, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=BTK抑制剂Calquence：显著缓解新冠病毒COVID-19感染患者体内的细胞因子风暴, objectType=article, longId=195498, objectId=094219549826, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=094219549826, replyNumber=0, likeNumber=39, createdTime=2021-04-22, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=094219549826, moduleTitle=BTK抑制剂Calquence：显著缓解新冠病毒COVID-19感染患者体内的细胞因子风暴, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=094219549826)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851026, encodeId=39ac1851026dc, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=FDA紧急授权将羟氯喹和氯喹，用于治疗特定类型的新冠病毒COVID-19感染患者, objectType=article, longId=191244, objectId=f588191244bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f588191244bc, replyNumber=0, likeNumber=34, createdTime=2020-06-08, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f588191244bc, moduleTitle=FDA紧急授权将羟氯喹和氯喹，用于治疗特定类型的新冠病毒COVID-19感染患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f588191244bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1851024, encodeId=b9201851024c0, content=<a href='/topic/show?id=0406580667c' target=_blank style='color:#2F92EE;'>#新冠病毒COVID-19#</a>, objectTitle=间充质干细胞治疗新冠病毒COVID-19感染的7名患者，均在14天内顺利出院, objectType=article, longId=191236, objectId=dbe619123601, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbe619123601, replyNumber=0, likeNumber=35, createdTime=2020-09-30, rootId=0, userName=yyanpro@21cn.c, userId=f00658, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbe619123601, moduleTitle=间充质干细胞治疗新冠病毒COVID-19感染的7名患者，均在14天内顺利出院, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbe619123601)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

新冠病毒COVID-19

2020-05-29

智慧医人 (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段

2021-06-08

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

地塞米松真的是新冠病毒COVID-19的突破吗？医生说先别着急

2020-10-06

智慧医人 (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

6000名患者回顾性研究：明确更有效的抗新冠病毒COVID-19细胞因子风暴疗法

2020-11-23

智慧医人 (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性

2021-01-11

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败

2020-12-07

智慧医人 (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

欧盟批准Gilead的remdesivir，治疗新冠病毒COVID-19感染

2021-03-01

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

流行病防范创新联盟发出呼吁，还有20亿美元的资金缺口可能会阻碍新冠病毒COVID-19疫苗的开发

2020-09-15

智慧医人 (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

新型干细胞疗法：治疗新冠病毒COVID-19相关性呼吸窘迫

2021-03-10

智慧医人 (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

FDA发布新冠病毒COVID-19疫苗批准的新指南

2021-09-22

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

西奈山索伦托合作开发针对新冠病毒COVID-19的三抗体联合疗法COVI-SHIELD

2020-05-09

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

Moderna将于7月开始，开展其新冠病毒COVID-19疫苗的关键3期试验

2020-12-02

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

礼来启动新冠病毒COVID-19抗体药物的全球临床试验

2021-03-03

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验

2020-08-03

智慧医人 (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

Moderna的新冠病毒COVID-19疫苗：计划定价为每疗程50-60美元

2020-08-12

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验

2021-01-09

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

Tiziana实现"肺部靶向递送"抗IL-6R单抗，以高效治疗新冠病毒COVID-19感染患者

2021-01-28

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

重磅！英国批准全球最佳治疗新冠病毒COVID-19的药物——地塞米松

2020-09-25

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

BTK抑制剂Calquence：显著缓解新冠病毒COVID-19感染患者体内的细胞因子风暴

2021-04-22

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

FDA紧急授权将羟氯喹和氯喹，用于治疗特定类型的新冠病毒COVID-19感染患者

2020-06-08

yyanpro@21cn.c (审核中...)

前往app查看评论内容

#新冠病毒COVID-19#

间充质干细胞治疗新冠病毒COVID-19感染的7名患者，均在14天内顺利出院

2020-09-30

科室
- - 订阅+
  - 更多科室
工具
服务